Press release centre
Past Press Releases - Evolva SA
December 14, 2009 Evolva raises additional CHF 21 million Listing on SIX Swiss Exchange under name Evolva Holding SA More
October 29, 2009 Evolva appoints Jessica Mann as Chief Medical Officer Evolva SA, a Swiss headquartered international biotech company has expanded its management team by appointing Jessica Mann as Chief Medical Officer. More
August 27, 2009 Evolva appoints Jutta Heim as chief technology officer Evolva SA, a Swiss headquartered international biotech company has expanded its Management team by appointing Jutta Heim as Chief Technology Officer. More
July 16, 2009 Evolva successfully completes Phase I single ascending dose trial on EV-077 Evolva successfully completes Phase I single ascending dose trial on EV-077 for renal and cardiovascular indications More
March 18, 2009 Evolva starts Phase I Clinical Trials on EV-077 Evolva SA, an international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has started Phase I Clinical Trials with its drug candidate EV-077-3201-2TBS. More
November 4, 2008 Evolva receives funding from the Global Cardiovascular Innovation Center Evolva today announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). More
November 8, 2006 Evolva announces $26.7 million award from the United States Defense Threat Reduction Agency Evolva Biotech, a biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, has received a $26.7 million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of therapeutics that improve the ability of humans to resist diverse pathogens, in particular potential biowarfare or bioterrorism agents. More
September 2, 2005 Evolva acquires pharmaceutical business of Poalis Evolva has acquired the pharmaceutical business and associated assets of Poalis. Evolva will integrate certain Poalis employees into Evolva’s existing Danish operations, and take over the running of the Poalis facility at KVL in Copenhagen. More
July 1, 2005 Evolva & AnalytiCon enter Nuclear Receptor Alliance Evolva Biotech and AnalytiCon Discovery GmbH have entered into a strategic alliance to jointly apply their respective technologies to the generation and optimization of novel nuclear receptor agonists and related compounds. More |